The National Institute of Allergy and Infectious Diseases (NIAID) recently launched a phase 2 clinical trial of an experimental universal influenza vaccine.
Because seasonal influenza vaccines differ year to year to match the strains predicted to circulate in the upcoming season, people must be vaccinated annually. However, influenza viruses mutate constantly, which can affect the efficacy of seasonal vaccines. A universal flu vaccine could address these challenges by protecting against a variety of flu strains, rather than a select few.
Rubin R. NIH-Sponsored Trial of Universal Influenza Vaccine. JAMA. 2018;319(24):2469. doi:10.1001/jama.2018.7886
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: